Kontour Medical Technology Stock Fundamentals
| 688314 Stock | 28.89 0.89 3.18% |
Kontour Medical Technology fundamentals help investors to digest information that contributes to Kontour Medical's financial success or failures. It also enables traders to predict the movement of Kontour Stock. The fundamental analysis module provides a way to measure Kontour Medical's intrinsic value by examining its available economic and financial indicators, including the cash flow records, the balance sheet account changes, the income statement patterns, and various microeconomic indicators and financial ratios related to Kontour Medical stock.
The current year's Research Development is expected to grow to about 17.6 M, whereas Tax Provision is forecasted to decline to about 13.7 M. Kontour | Select Account or Indicator |
Kontour Medical Technology Company EBITDA Analysis
Kontour Medical's EBITDA stands for earnings before interest, taxes, depreciation, and amortization. It is a measure of a company operating cash flow based on data from the company income statement and is a very good way to compare companies within industries or across different sectors. However, unlike Operating Cash Flow, EBITDA does not include the effects of changes in working capital.
Current Kontour Medical EBITDA | 106.76 M |
Most of Kontour Medical's fundamental indicators, such as EBITDA, are part of a valuation analysis module that helps investors searching for stocks that are currently trading at higher or lower prices than their real value. If the real value is higher than the market price, Kontour Medical Technology is considered to be undervalued, and we provide a buy recommendation. Otherwise, we render a sell signal.
In a nutshell, EBITDA is calculated by adding back each of the excluded items to the post-tax profit, and can be used to compare companies with very different capital structures.
| Competition |
Kontour Ebitda
Ebitda |
|
According to the company disclosure, Kontour Medical Technology reported earnings before interest,tax, depreciation and amortization of 106.76 M. This is 87.83% lower than that of the Health Care Equipment & Supplies sector and significantly higher than that of the Health Care industry. The ebitda for all China stocks is 97.26% higher than that of the company.
Kontour Medical Tech Fundamental Drivers Relationships
Comparative valuation techniques use various fundamental indicators to help in determining Kontour Medical's current stock value. Our valuation model uses many indicators to compare Kontour Medical value to that of its competitors to determine the firm's financial worth. You can analyze the relationship between different fundamental ratios across Kontour Medical competition to find correlations between indicators driving Kontour Medical's intrinsic value. More Info.Kontour Medical Technology is the top company in current valuation category among its peers. It also is number one stock in price to book category among its peers . The ratio of Current Valuation to Price To Book for Kontour Medical Technology is about 545,809,718 . Comparative valuation analysis is a catch-all model that can be used if you cannot value Kontour Medical by discounting back its dividends or cash flows. This model doesn't attempt to find an intrinsic value for Kontour Medical's Stock. Still, instead, it compares the stock's price multiples to a benchmark or nearest competition to determine if the stock is relatively undervalued or overvalued.Kontour EBITDA Peer Comparison
Stock peer comparison is one of the most widely used and accepted methods of equity analyses. It analyses Kontour Medical's direct or indirect competition against its EBITDA to detect undervalued stocks with similar characteristics or determine the stocks which would be a good addition to a portfolio. Peer analysis of Kontour Medical could also be used in its relative valuation, which is a method of valuing Kontour Medical by comparing valuation metrics of similar companies.Kontour Medical is currently under evaluation in ebitda category among its peers.
Kontour Fundamentals
| Current Valuation | 2.01 B | ||||
| Price To Book | 3.68 X | ||||
| Price To Sales | 7.61 X | ||||
| Revenue | 275.03 M | ||||
| EBITDA | 106.76 M | ||||
| Net Income | 75.51 M | ||||
| Total Debt | 37.97 M | ||||
| Cash Flow From Operations | 85.22 M | ||||
| Total Asset | 675.79 M | ||||
| Retained Earnings | 164.9 M | ||||
| Working Capital | 346.95 M | ||||
| Annual Yield | 0.01 % | ||||
| Net Asset | 675.79 M |
About Kontour Medical Fundamental Analysis
The Macroaxis Fundamental Analysis modules help investors analyze Kontour Medical Technology's financials across various querterly and yearly statements, indicators and fundamental ratios. We help investors to determine the real value of Kontour Medical using virtually all public information available. We use both quantitative as well as qualitative analysis to arrive at the intrinsic value of Kontour Medical Technology based on its fundamental data. In general, a quantitative approach, as applied to this company, focuses on analyzing financial statements comparatively, whereas a qaualitative method uses data that is important to a company's growth but cannot be measured and presented in a numerical way.
Please read more on our fundamental analysis page.| Last Reported | Projected for Next Year | ||
| Total Revenue | 275 M | 228.7 M | |
| Cost Of Revenue | 51.8 M | 42 M |
Currently Active Assets on Macroaxis
Other Information on Investing in Kontour Stock
Kontour Medical financial ratios help investors to determine whether Kontour Stock is cheap or expensive when compared to a particular measure, such as profits or enterprise value. In other words, they help investors to determine the cost of investment in Kontour with respect to the benefits of owning Kontour Medical security.